Realizing the potential of agonistic antibody immunotherapy.

Recent mechanistic insights into agonistic antibodies have the potential to enhance their clinical efficacy and safety in immunotherapy.

• Why it matters: Agonistic antibodies have shown limited benefit in patients despite their promise, highlighting the need to better understand their mechanisms to unlock their full therapeutic potential.
• What they did: Researchers reviewed recent progress in understanding how agonistic antibodies trigger receptor signalling, focusing on tumour necrosis factor receptor superfamily proteins and immune/cytokine receptors, and examined the clinical landscape.
• The result: These insights are expected to broaden the clinical applications of agonistic antibody immunotherapy and improve its safety and efficacy.